Acorda Therapeutics, Inc. (ACOR) Stock
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Acorda Therapeutics, Inc. is headquartered in US.
Acorda Therapeutics, Inc. (ACOR) stock trades at $0.66 with a market capitalization of $821028. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of -0.01, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.61 and $24.20, and currently trades 97.3% below its 52-week high.
On profitability, Acorda Therapeutics, Inc. generates a return on equity (ROE) of 786.07% — well above the market average, a sign of a high-quality business, return on capital employed of 21.14%, an operating margin of -19.78%, a net profit margin of -214.95%.
Official website: www.acorda.com